Your browser doesn't support javascript.
loading
In vitro effect of eltrombopag alone and in combination with azacitidine on megakaryopoiesis in patients with myelodysplastic syndrome.
D'Alò, Francesco; Zangrilli, Ilaria; Cupelli, Elisa; Fianchi, Luana; Criscuolo, Marianna; Falconi, Giulia; Fabiani, Emiliano; Pagano, Livio; Hohaus, Stefan; De Stefano, Valerio.
Afiliação
  • D'Alò F; Dipartimento Di Diagnostica per Immagini, Radioterapia Oncologica Ed Ematologia, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, Italy.
  • Zangrilli I; Sezione Di Ematologia, Dipartimento Di Scienze Radiologiche Ed Ematologiche, Università Cattolica Del Sacro Cuore, Roma, Italy.
  • Cupelli E; Dipartimento Di Diagnostica per Immagini, Radioterapia Oncologica Ed Ematologia, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, Italy.
  • Fianchi L; Dipartimento Di Diagnostica per Immagini, Radioterapia Oncologica Ed Ematologia, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, Italy.
  • Criscuolo M; Dipartimento Di Diagnostica per Immagini, Radioterapia Oncologica Ed Ematologia, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, Italy.
  • Falconi G; Dipartimento Di Diagnostica per Immagini, Radioterapia Oncologica Ed Ematologia, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, Italy.
  • Fabiani E; Dipartimento Di Biomedicina E Prevenzione, Università Di Roma Tor Vergata, Roma, Italy.
  • Pagano L; Dipartimento Di Biomedicina E Prevenzione, Università Di Roma Tor Vergata, Roma, Italy.
  • Hohaus S; Dipartimento Di Diagnostica per Immagini, Radioterapia Oncologica Ed Ematologia, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, Italy.
  • De Stefano V; Sezione Di Ematologia, Dipartimento Di Scienze Radiologiche Ed Ematologiche, Università Cattolica Del Sacro Cuore, Roma, Italy.
Platelets ; 32(3): 378-382, 2021 Apr 03.
Article em En | MEDLINE | ID: mdl-32268817
Thrombocytopenia is a severe complication for patients with myelodysplastic syndrome (MDS). Eltrombopag increases platelet count in MDS patients but its combination with azacitidine elicited controversial results. We aimed to quantify the colony forming units of megakaryocytes (CFU-Mk) obtained from CD34+ bone marrow cells isolated from patients with MDS and from healthy donors that were cultured in vitro in the presence or absence of azacitidine and with or without the sequential addition of eltrombopag to the culture medium. CD34+ bone marrow cells from 6 MDS patients and 3 controls were expanded in vitro and cultured for 3 days with or without azacitidine. Subsequently, a CFU-Mk assay was performed in presence or absence of eltrombopag. The addition of eltrombopag in the CFU-Mk assay after mock treatment of CD34+ cells increased the number of CFU-Mk in both controls and patients. On the contrary, using azacitidine pretreated CD34+ cells, eltrombopag minimally increased CFU-Mk in controls and produced heterogeneous response in MDS patients with no change in two patients and CFU-Mk increase in four patients. In vitro CFU-Mk assay suggest that some MDS patients are likely to benefit from the sequential addition of eltrombopag after azacitidine treatment, in the context of a personalized medicine.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Pirazóis / Azacitidina / Benzoatos / Síndromes Mielodisplásicas / Protocolos de Quimioterapia Combinada Antineoplásica / Trombopoese / Hidrazinas Limite: Adult / Aged / Aged80 / Humans / Middle aged Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Pirazóis / Azacitidina / Benzoatos / Síndromes Mielodisplásicas / Protocolos de Quimioterapia Combinada Antineoplásica / Trombopoese / Hidrazinas Limite: Adult / Aged / Aged80 / Humans / Middle aged Idioma: En Ano de publicação: 2021 Tipo de documento: Article